Anixa claims drug shows signs of superiority over Paxlovid

25 January 2022

Californian biotech Anixa Biosciences (Nasdaq: ANIX) and its partner MolGenie have claimed that they have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus.

Nirmatrelvir is the main component of Pfizer's (NYSE: PFE) Paxlovid, which was recently authorized to treat COVID-19. Paxlovid also includes ritonavir, which is an HIV drug.

"It's clear that more COVID-19 therapies—particularly inexpensive, room temperature-stable, oral therapies with improved pharmaco-dynamic properties—are needed"Amit Kumar, president, chief executive and chairman of Anixa, said: “We're pleased to report additional progress on our COVID-19 program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK